A recent study found that elevated CSF, but not serum, GFAP levels obtained at onset of treatment in a cohort of patients with relapse and progressive onset MS was associated with increased risk for subsequent disability progression [56], hence the optimal fluid for assessing GFAP levels may not yet be certain. The gene discussed is GFAP; the disease is myeloid sarcoma.